Fulcrum Therapeutics (NASDAQ:FULC) Shares Down 5.7% – Should You Sell?

by · The Cerbat Gem

Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) was down 5.7% during mid-day trading on Tuesday . The stock traded as low as $12.13 and last traded at $12.0550. Approximately 157,237 shares traded hands during mid-day trading, a decline of 79% from the average daily volume of 752,741 shares. The stock had previously closed at $12.78.

Analyst Ratings Changes

A number of brokerages have weighed in on FULC. Stifel Nicolaus set a $25.00 price objective on Fulcrum Therapeutics in a research note on Monday, December 8th. Bank of America lifted their price objective on shares of Fulcrum Therapeutics from $6.00 to $7.00 and gave the company an “underperform” rating in a research note on Tuesday, December 9th. Wall Street Zen upgraded shares of Fulcrum Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Wednesday, October 8th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $23.00 price objective (up from $16.00) on shares of Fulcrum Therapeutics in a research note on Monday, December 8th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $19.00.

Check Out Our Latest Report on Fulcrum Therapeutics

Fulcrum Therapeutics Stock Performance

The company has a market cap of $645.65 million, a price-to-earnings ratio of -10.13 and a beta of 3.17. The company has a 50-day simple moving average of $10.17 and a 200-day simple moving average of $8.36.

Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) last released its quarterly earnings data on Wednesday, October 29th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.02). As a group, equities research analysts forecast that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current year.

Insider Buying and Selling

In other Fulcrum Therapeutics news, Director Robert J. Gould sold 15,000 shares of the business’s stock in a transaction on Wednesday, November 19th. The stock was sold at an average price of $11.03, for a total transaction of $165,450.00. Following the sale, the director directly owned 484,864 shares in the company, valued at approximately $5,348,049.92. The trade was a 3.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the firm’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $13.98, for a total value of $58,368,443.22. Following the completion of the transaction, the insider owned 6,053,960 shares of the company’s stock, valued at approximately $84,634,360.80. This represents a 40.82% decrease in their position. The SEC filing for this sale provides additional information. 7.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Fulcrum Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Algert Global LLC grew its position in shares of Fulcrum Therapeutics by 6.0% in the first quarter. Algert Global LLC now owns 36,147 shares of the company’s stock valued at $104,000 after purchasing an additional 2,030 shares during the last quarter. Vanguard Personalized Indexing Management LLC grew its holdings in Fulcrum Therapeutics by 26.1% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 12,943 shares of the company’s stock valued at $89,000 after buying an additional 2,677 shares during the last quarter. Strs Ohio increased its position in Fulcrum Therapeutics by 3.7% during the third quarter. Strs Ohio now owns 77,900 shares of the company’s stock worth $717,000 after buying an additional 2,800 shares in the last quarter. American Century Companies Inc. raised its holdings in shares of Fulcrum Therapeutics by 2.6% in the first quarter. American Century Companies Inc. now owns 123,711 shares of the company’s stock worth $356,000 after acquiring an additional 3,100 shares during the last quarter. Finally, Farther Finance Advisors LLC lifted its position in shares of Fulcrum Therapeutics by 108.3% in the third quarter. Farther Finance Advisors LLC now owns 7,112 shares of the company’s stock valued at $65,000 after acquiring an additional 3,697 shares in the last quarter. 89.83% of the stock is currently owned by hedge funds and other institutional investors.

Fulcrum Therapeutics Company Profile

(Get Free Report)

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.

Featured Stories